98%
921
2 minutes
20
IL-7Rα expression has been suggested to be involved in the development of cancer and has been reported to be linked to poor overall survival in patients with lung cancer. However, no evidence has been reportedregarding the significance of IL-7Rα expression in gastric adenocarcinoma (GA) untilnow. In the present investigation, to understand the clinicopathological significance of IL-7Rα expression in GA, expression of IL-7Rα was evaluated using immunohistochemistry in 121 cases of paired GA and its corresponding normal controls. As further confirmation, detection of IL-7Rα expression was extended from the protein level to the mRNA level using qRT-PCR. Clinicopathological association was statistically analyzed between IL-7Rα expression and clinicopathological variables, including demographic, T classification, clinical stage, lymph nodes metastases, differentiation, recurrence or not, and overall prognosis. IL-7Rα expression was markedly up-regulated in GA tissues relative to paired normal controls at both the protein or mRNA level. Elevation of IL-7Rα was markedly associated with lymph nodes metastases (=0.006), differentiation (=0.005), recurrence (=0.043), and poor overall prognosis (=0.039). There were trends toward statistical significance forboth T classification (=0.063) and clinical stage (=0.065) despite no significant associations found. Together, our study is the first toanalyze the significance of IL-7Rα expression in GA, suggesting its potential predictive value for recurrence and overall prognosis.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6958162 | PMC |
Crit Rev Immunol
January 2025
Otorhinolaryngology Head and Neck Surgery, The Second Affiliated Hospital of Nanchang University, Nanchang, Jiangxi, China.
Galectin-10(Gal-10)/CLC(Charcot-Leyden crystal) has been discovered to be related to ECRSwNP characterized by high eosinophilic infiltration. We aimed to investigate the effects of Gal-10 on ECRSwNP. A total of 36 tissue samples were collected, including 11 ECRSwNP samples, 15 non-ECRSwNP samples, and 10 Control samples.
View Article and Find Full Text PDFJ Environ Pathol Toxicol Oncol
January 2025
Department of General Surgery, Xiangshan First People's Hospital Medical and Health Group, Ningbo 315700, China.
Breast cancer (BC) is one of the main causes of cancer-related death in women. The purpose of this study was to evaluate the expression of miR-605-5p in BC and its diagnostic and prognostic value. BC patients and healthy individuals who met the study criteria were included.
View Article and Find Full Text PDFJ Environ Pathol Toxicol Oncol
January 2025
Department of Oncology, Jiangsu Cancer Hospital & Jiangsu Institute of Cancer Research & The Affiliated Cancer Hospital of Nanjing Medical University, Nanjing 210009, China.
Noncoding RNA regulatory networks play crucial roles in human breast cancer. The aim of this study was to establish a network containing multi-type RNAs and RBPs in triple-negative breast cancer (TNBC). Differential expression analyses of lncRNAs, miRNAs, and genes were performed using the GEO2R tool.
View Article and Find Full Text PDFJ Environ Pathol Toxicol Oncol
January 2025
Department of Clinical Laboratory Medicine, Fujian Medical University, Fuzhou, China.
Invasive ductal carcinoma (IDC) is a major type of breast cancer. The utilization of inhibitors targeting histone methyltransferases introduces novel therapeutic avenues for the treatment of cancer. Immunohistochemistry, Western blot, and reverse transcription quantitative polymerase chain reaction experiments were applied to assess the levels of EHMT2 in IDC and adjacent tissues.
View Article and Find Full Text PDFJ Environ Pathol Toxicol Oncol
January 2025
Department of Pharmacy, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, P.R. China.
Despite advancements in systemic therapy, the mortality rate for patients with metastatic melanoma remains around 70%, underscoring the imperative for alternative treatment strategies. Through the establishment of a chemoresistant melanoma model and a subsequent drug investigation, we have identified pacritinib, a medication designed for treating myelofibrosis and severe thrombocytopenia, as a potential candidate to overcome resistance to melanoma therapy. Our research reveals that pacritinib, administered at clinically achievable concentrations, effectively targets dacarbazine-resistant melanoma cells by suppressing IRAK1 rather than JAK2.
View Article and Find Full Text PDF